Not Yet RecruitingNot Applicable

Critical Illness After Hematopoietic Cell Transplantation

China4,000 participantsStarted 2026-01-01

Plain-language summary

This is a prospective, multicenter observational trial for patients who develop critical illness after hematopoietic cell transplantation. Patients who are admitted to the intensive care unit after undergoing hematopoietic cell transplantation at the participating medical centers will be enrolled in this study. The clinical characteristics, laboratory profiles, managements, and clinical outcomes will be prospectively collected.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who underwent hematopoietic cell transplantation at any of the participating medical centers. * Patients who are admitted to ICU for the management of critical illness following hematopoietic cell transplantation. Exclusion Criteria: * Admitted to ICU for a reason other than critical illness (e.g., routine postoperative monitoring) and discharged within 2 days of ICU admission. * Unavailable in-ICU clinical outcomes or absent key baseline characteristics. * Any other conditions that, in the opinion of the investigator, can interfere with the interpretation of data.

What they're measuring

Overall survival

Timeframe: Before ICU discharge; within 6 months after ICU discharge; and within 1 year after ICU discharge.

Trial details

NCT IDNCT07328724

SponsorPeking University People's Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2036-06-30

Contact for this trial

Xiao Hui Zhang, MD

861088324577 zhangxh@bjmu.edu.cn

View on ClinicalTrials.gov More Critical Illness trials